bufotenine (5-hydroxy-N,N-dimethyltryptamine); mebufotenine (GH001, 5-MeO-DMT)
Jump to navigation
Jump to search
Indications
- inhaled psychedelic mebufotenin may improve depression symptoms in patients with treatment-resistant depression[2]
Dosage
- individually-dosed inhaled mebufotenin
- 3 escalating doses (6, 12, & 18 mg) on a single day with a 1-hour interval between doses[2]
Pharmacokinetics
- metabolized primarily by type A monoamine oxidase to 5-hydroxyindoleacetic acid (5-HIAA) in rats
- unlike serotonin, bufotenine is not stored in platelets,
- mebufotenin is a rapid-acting psychoactive molecule[2]
Mechanism of action
- serotonin analog reported to have hallucinogenic properties[1]
- bufotenine has poor blood-brain barrier penetration
- mebufotenin acts as a nonselective serotonin (5-HT) agonist with high affinity for the 5-HT1A receptor subtype[2]
More general terms
References
- ↑ 1.0 1.1 1.2 Fuller RW, Snoddy HD, Perry KW. Tissue distribution, metabolism and effects of bufotenine administered to rats. Neuropharmacology. 1995 Jul;34(7):799-804. PMID: https://pubmed.ncbi.nlm.nih.gov/8532147
- ↑ 2.0 2.1 2.2 2.3 2.4 Cubala WJ, Bajbouj M, Bauer M et al GH001 vs Placebo in Patients With Treatment-Resistant Depression: A Randomized Clinical Trial. JAMA Psychiatry. 2026 Mar 25. PMID: https://pubmed.ncbi.nlm.nih.gov/41879760 https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2846834